Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
NRIX Stock Chart & Stats
$17.20
$0.42(2.22%)
At close: 4:00 PM EST
$17.20
$0.42(2.22%)
Day’s Range― - ―
52-Week Range$8.18 - $23.00
Previous CloseN/A
Volume302.00K
Average Volume (3M)1.84M
Market Cap
$1.72B
Enterprise Value$413.71M
Total Cash (Recent Filing)$428.83M
Total Debt (Recent Filing)$56.49M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Feb 18, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding101,369,230
10 Day Avg. Volume1,760,683
30 Day Avg. Volume1,840,478
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)2.82
Price to Sales (P/S)27.21
P/FCF Ratio-8.16
Enterprise Value/Market Cap0.24
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit-3.04
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
$25.40Price Target Upside47.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.13
Revenue Forecast (FY)$86.05M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe updated data from the trial showed that bexobrutideg has improved safety data and maintained efficacy in relapsed/refractory chronic lymphocytic leukemia patients.
Financial StrategyA $250M private placement will support ongoing clinical development, extending runway into 2028.
Regulatory ApprovalNurix received the greenlight from the FDA and ex-US regulators to advance the 600 mg QD dose of bexobrutideg into pivotal r/r CLL studies.
Bears Say
Financial PerformanceNurix reported a net loss of $1.03 per share, which is wider than the previously estimated net loss of $0.68 per share.
Market RisksRisks include negative clinical proof-of-concept for either NX-2127, NX-5948, NX-1607, failure to obtain timely approval for pipeline candidates, and poorer-than-anticipated product market uptake.
Revenue PerformanceNurix reported $7.9M in collaboration/license revenue, which is below the previously estimated $30M.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $8.18 and its highest was $23.00 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Nurix Therapeutics’s market cap is $1.72B.
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Feb 18, 2026 which is in 82 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Oct 09, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.817 by -$0.213.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -0.96.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 101,369,230 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.817. Following the earnings report the stock price went up 8.818%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Currently, no hedge funds are holding shares in NRIX
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.40 (47.67% Upside)
$25.40 (47.67% Upside)
Blogger Sentiment
Neutral
NRIX Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 211.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.22%
12-Months-Change
Fundamentals
Return on Equity
-65.35%
Trailing 12-Months
Asset Growth
1.73%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
NRIX Stock 12 Month Forecast
Average Price Target
$25.40
▲(47.67% Upside)
Technical Analysis
Arvinas Holding Company
―
Vir Biotechnology
―
Relay Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
4.87% Insiders
20.57% Mutual Funds
35.04% Other Institutional Investors
21.45% Public Companies and
Individual Investors